Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

[1]  Nuria Barbarroja,et al.  Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus , 2014, Annals of the rheumatic diseases.

[2]  N. Key,et al.  Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. , 2014, Thrombosis research.

[3]  G. Holtrop,et al.  Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status , 2014, Journal of Thrombosis and Thrombolysis.

[4]  T. Luther,et al.  Platelet tissue factor: to be or not to be. , 2013, Thrombosis research.

[5]  L. Punzi,et al.  Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome , 2013, Thrombosis and Haemostasis.

[6]  R. Touyz,et al.  Microparticles: biomarkers and beyond. , 2013, Clinical science.

[7]  N. Mackman,et al.  Microvesicles as risk markers for venous thrombosis , 2013, Expert review of hematology.

[8]  D. Neuberg,et al.  Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study) , 2013, British journal of haematology.

[9]  A. Viera,et al.  Microparticles in cardiovascular disease pathophysiology and outcomes. , 2012, Journal of the American Society of Hypertension : JASH.

[10]  M. Bruzelius,et al.  Studies of microparticles in patients with the antiphospholipid syndrome (APS) , 2012, Lupus.

[11]  K. Williams,et al.  Microvesicles: potential markers and mediators of endothelial dysfunction , 2012, Current opinion in endocrinology, diabetes, and obesity.

[12]  P. Mannucci,et al.  Circulating microparticles and risk of venous thromboembolism. , 2009, Thrombosis research.

[13]  N. Mackman,et al.  Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. , 2012, Thrombosis research.

[14]  Ken Jacobson,et al.  Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. , 2011, Blood.

[15]  N. Mackman,et al.  Microparticles in Hemostasis and Thrombosis , 2011, Circulation research.

[16]  B. Furie,et al.  β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. , 2011, Blood.

[17]  P. Brunet,et al.  Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis , 2010, Thrombosis and Haemostasis.

[18]  D. Isenberg,et al.  Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways , 2010, The Journal of Immunology.

[19]  J. Zwicker.  Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. , 2010, Thrombosis research.

[20]  P. D. de Groot,et al.  The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.

[21]  X. Mariette,et al.  Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity , 2009, Arthritis research & therapy.

[22]  D. Isenberg,et al.  In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  J. Freyssinet,et al.  Circulating procoagulant microparticles in patients with venous thromboembolism. , 2009, Thrombosis research.

[24]  J. V. van Mourik,et al.  Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[25]  A. Khorana,et al.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.

[26]  Pojen P. Chen,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms , 2008, Seminars in thrombosis and hemostasis.

[27]  G. Valesini,et al.  Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts , 2007 .

[28]  R. Derksen,et al.  Platelet adhesion to dimeric β2‐glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2′ , 2007, Journal of thrombosis and haemostasis : JTH.

[29]  S. Rahgozar,et al.  Current concepts on the pathogenesis of the antiphospholipid syndrome. , 2007, Blood.

[30]  L. Horstman,et al.  Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. , 2007, Thrombosis research.

[31]  G. M. Iverson,et al.  Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. , 2006, Arthritis and rheumatism.

[32]  C. Sáez,et al.  Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.

[33]  F. Rosendaal,et al.  Lupus anticoagulants and the risk of a first episode of deep venous thrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[34]  K. McCrae,et al.  Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. , 2005, Blood.

[35]  S. Pierangeli,et al.  Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. , 2004, Arthritis & Rheumatism.

[36]  F. Dignat-George,et al.  Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome , 2004, Thrombosis and Haemostasis.

[37]  Pojen P. Chen,et al.  Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. , 2003, The American journal of pathology.

[38]  J. Hall,et al.  E‐Selectin mediates pathogenic effects of antiphospholipid antibodies , 2003, Journal of thrombosis and haemostasis : JTH.

[39]  J. Rand.  Molecular Pathogenesis of the Antiphospholipid Syndrome , 2002, Circulation research.

[40]  C. Esmon,et al.  Antiphospholipid antibodies and the protein C pathway. , 2000, Journal of autoimmunity.

[41]  G. Grau,et al.  In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. , 1999, The Journal of clinical investigation.

[42]  S. Shapiro,et al.  Lupus anticoagulants and antiphospholipid antibodies. , 1998, Hematology/oncology clinics of North America.

[43]  M. Khamashta,et al.  Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. , 1997, Arthritis and rheumatism.

[44]  A. Biasiolo,et al.  Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies , 1996, Thrombosis and Haemostasis.

[45]  J. Lasala,et al.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies. , 1995, The Journal of clinical investigation.

[46]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.

[47]  G. Rodgers,et al.  Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. , 1993, American journal of obstetrics and gynecology.

[48]  Hunt,et al.  A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection , 1992, Lupus.

[49]  Marcus John Beasley,et al.  Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. , 1992, Clinical and experimental rheumatology.

[50]  T. Barbui,et al.  Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin , 1991, Thrombosis and Haemostasis.

[51]  A. DeMichele,et al.  Detection of endothelial cell‐reactive immunoglobulin in patients with anti‐phospholipid antibodies , 1991, British journal of haematology.

[52]  T. Koike,et al.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease , 1990, The Lancet.

[53]  C. Esmon,et al.  Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. , 1990, The Journal of biological chemistry.

[54]  P. Bagros,et al.  Cyclosporin-induced muscular toxicity , 1990, The Lancet.

[55]  M. Khamashta,et al.  Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. , 1988, Clinical and experimental immunology.